ranked for Transfer Pricing (TP)
Know when to call Eli Lilly and Company — before your competition does. kelvy agents monitor events in real time and surface ranked opportunities for Accounting & Tax firms.
InnoCare Pharma and Lilly Sign Research Collaboration and License Agreement for New Medicines
InnoCare Pharma announced on Sept. 24, 2026, a strategic research collaboration and license agreement with Lilly to develop new medicines. InnoCare Pharma is a biopharmaceutical company listed on HKEX under 09969 and SSE under 688428; financial and other terms were not included in the provided excerpt.
Highlighted Opportunity
IP Migration / DEMPE Analysis
Both companies need to define IP ownership and development returns before research advances
The collaboration requires clear treatment of licensed IP and value created through each party’s research contributions.
Track company & unlock full analysisEli Lilly to acquire psychedelic company for $360 million
Eli Lilly has agreed to acquire a psychedelic drug developer from a billionaire founder in a deal valued at $360 million. The transaction involves the sale of the entire company, with the founder receiving the full proceeds.
Highlighted Opportunity
IP Migration / DEMPE Analysis
Lilly must document ownership and valuation of acquired psychedelic IP
Acquiring a drug developer brings heavy IP assets (patents, compounds, data) that must be valued and mapped into Lilly's existing IP structure.
Track company & unlock full analysisWe'll prefill Transfer Pricing (TP) and this company so you land in a personal feed of ranked opportunities — not a blank account.
Public preview. Create an account to personalize scoring and digests.